Literature DB >> 10601244

Cholesteryl ester transfer protein corrects dysfunctional high density lipoproteins and reduces aortic atherosclerosis in lecithin cholesterol acyltransferase transgenic mice.

B Föger1, M Chase, M J Amar, B L Vaisman, R D Shamburek, B Paigen, J Fruchart-Najib, J A Paiz, C A Koch, R F Hoyt, H B Brewer, S Santamarina-Fojo.   

Abstract

Expression of human lecithin cholesterol acyltransferase (LCAT) in mice (LCAT-Tg) leads to increased high density lipoprotein (HDL) cholesterol levels but paradoxically, enhanced atherosclerosis. We have hypothesized that the absence of cholesteryl ester transfer protein (CETP) in LCAT-Tg mice facilitates the accumulation of dysfunctional HDL leading to impaired reverse cholesterol transport and the development of a pro-atherogenic state. To test this hypothesis we cross-bred LCAT-Tg with CETP-Tg mice. On both regular chow and high fat, high cholesterol diets, expression of CETP in LCAT-Tg mice reduced total cholesterol (-39% and -13%, respectively; p < 0.05), reflecting a decrease in HDL cholesterol levels. CETP normalized both the plasma clearance of [(3)H]cholesteryl esters ([(3)H]CE) from HDL (fractional catabolic rate in days(-1): LCAT-Tg = 3.7 +/- 0.34, LCATxCETP-Tg = 6.1 +/- 0.16, and controls = 6.4 +/- 0.16) as well as the liver uptake of [(3)H]CE from HDL (LCAT-Tg = 36%, LCATxCETP-Tg = 65%, and controls = 63%) in LCAT-Tg mice. On the pro-atherogenic diet the mean aortic lesion area was reduced by 41% in LCATxCETP-Tg (21.2 +/- 2.0 micrometer(2) x 10(3)) compared with LCAT-Tg mice (35.7 +/- 2.0 micrometer(2) x 10(3); p < 0.001). Adenovirus-mediated expression of scavenger receptor class B (SR-BI) failed to normalize the plasma clearance and liver uptake of [(3)H]CE from LCAT-Tg HDL. Thus, the ability of SR-BI to facilitate the selective uptake of CE from LCAT-Tg HDL is impaired, indicating a potential mechanism leading to impaired reverse cholesterol transport and atherosclerosis in these animals. We conclude that CETP expression reduces atherosclerosis in LCAT-Tg mice by restoring the functional properties of LCAT-Tg mouse HDL and promoting the hepatic uptake of HDL-CE. These findings provide definitive in vivo evidence supporting the proposed anti-atherogenic role of CETP in facilitating HDL-mediated reverse cholesterol transport and demonstrate that CETP expression is beneficial in pro-atherogenic states that result from impaired reverse cholesterol transport.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10601244     DOI: 10.1074/jbc.274.52.36912

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  52 in total

Review 1.  Low high-density lipoprotein cholesterol: physiological background, clinical importance and drug treatment.

Authors:  Martin Hersberger; Arnold von Eckardstein
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 2.  The HDL hypothesis: does high-density lipoprotein protect from atherosclerosis?

Authors:  Menno Vergeer; Adriaan G Holleboom; John J P Kastelein; Jan Albert Kuivenhoven
Journal:  J Lipid Res       Date:  2010-04-06       Impact factor: 5.922

3.  Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure.

Authors:  Guoqing Cao; Thomas P Beyer; Youyan Zhang; Robert J Schmidt; Yan Q Chen; Sandra L Cockerham; Karen M Zimmerman; Sotirios K Karathanasis; Ellen A Cannady; Todd Fields; Nathan B Mantlo
Journal:  J Lipid Res       Date:  2011-09-25       Impact factor: 5.922

4.  The ATP binding cassette transporter A1 (ABCA1) modulates the development of aortic atherosclerosis in C57BL/6 and apoE-knockout mice.

Authors:  Charles W Joyce; Marcelo J A Amar; Gilles Lambert; Boris L Vaisman; Beverly Paigen; Jamila Najib-Fruchart; Robert F Hoyt; Edward D Neufeld; Alan T Remaley; Donald S Fredrickson; H Bryan Brewer; Silvia Santamarina-Fojo
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-18       Impact factor: 11.205

Review 5.  Novel HDL-directed pharmacotherapeutic strategies.

Authors:  Emil M Degoma; Daniel J Rader
Journal:  Nat Rev Cardiol       Date:  2011-01-18       Impact factor: 32.419

Review 6.  HDL and atherosclerotic cardiovascular disease: genetic insights into complex biology.

Authors:  Robert S Rosenson; H Bryan Brewer; Philip J Barter; Johan L M Björkegren; M John Chapman; Daniel Gaudet; Daniel Seung Kim; Eric Niesor; Kerry-Anne Rye; Frank M Sacks; Jean-Claude Tardif; Robert A Hegele
Journal:  Nat Rev Cardiol       Date:  2017-08-10       Impact factor: 32.419

Review 7.  Cholesteryl Ester Transfer Protein Inhibitors - Future Soon to be REVEALed.

Authors:  Christopher Huggins; Nicoletta Charolidi; Gillian W Cockerill
Journal:  Eur Cardiol       Date:  2015-07

Review 8.  Inhibition of cholesteryl ester transfer protein activity: a new therapeutic approach to raising high-density lipoprotein.

Authors:  Daniel J Rader
Journal:  Curr Atheroscler Rep       Date:  2004-09       Impact factor: 5.113

9.  Low cholesteryl ester transfer protein and phospholipid transfer protein activities are the factors making tree shrew and beijing duck resistant to atherosclerosis.

Authors:  Hui-rong Liu; Gang Wu; Bing Zhou; Bao-sheng Chen
Journal:  Lipids Health Dis       Date:  2010-10-12       Impact factor: 3.876

10.  Association of circulating cholesteryl ester transfer protein activity with incidence of cardiovascular disease in the community.

Authors:  Ramachandran S Vasan; Michael J Pencina; Sander J Robins; Justin P Zachariah; Guneet Kaur; Ralph B D'Agostino; Jose M Ordovas
Journal:  Circulation       Date:  2009-12-15       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.